Advancing heart failure care through clinical trials + outcomes research
Tufts Medical Center has a rich history of research and innovation. We were high enrollers in the Medtronic HVAD clinical trial and was the first center in New England to implant the novel Evaheart 2 LVAD. We are also a clinical site in the INNOVATE clinical trial of the BrioVAD. Tufts Medical Center is the founding member of the Cardiogenic Shock Working Group, which continues to drive innovation in cardiogenic shock diagnosis, management, and outcomes research worldwide. Faculty at Tufts Medical Center participate in several other investigator-initiated and industry-sponsored studies, and we have a robust internal transplant and LVAD database used for quality improvement and clinical research.
For incoming fellows looking for a basic science research experience, Tufts Medical Center houses the Molecular Cardiology Research Institute (MCRI). With more than 25 years of pioneering discovery, the MCRI unites 12 principal investigators and over 40 researchers and trainees across three centers: the Cardiac Biology Research Center, the Vascular Biology Research Center, and the Center for Translational Pharmacology and Genomics. Fellows can pursue projects spanning the full translational spectrum, from molecular mechanisms of heart attack, hypertension, heart failure, and arrhythmia to drug and device development, cardio-oncology, sex differences in cardiovascular disease, and biobank-driven genetic studies, with a clear pathway to multicenter clinical trials born from MCRI discoveries.
